Prosecution Insights
Prosecution Insights
12 pending office actions • 9 art units • 12 examiners • 2 of 12 (17%) have an AI response strategy ready • 38 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (8%) |
| §103 only | 5 (42%) |
| §102 only | 1 (8%) |
| No statute on record | 5 (42%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, PO-CHIH | 1 | 74.7% | +13.9% |
| GAO, ASHLEY HARTMAN | 1 | 59.8% | +38.9% |
| REDDIG, PETER J | 1 | 58.0% | +40.0% |
| REDWOOD, CHRISTOPHER EVAN | 1 | — | — |
| DEKARSKE, MADELINE MCGUIRE | 1 | — | — |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 60.1% | +25.4% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.3% | +48.6% |
| GOTFREDSON, GAREN | 1 | 40.0% | +29.1% |
| NATARAJAN, MEERA | 1 | 62.2% | +16.8% |
| JARRELL, NOBLE E | 1 | 81.3% | +9.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18330141 | COMBINATION THERAPY OF ANTI-PD-1 ACTIVE AGENT, ANTI-TIM-3 ACTIVE AGENT, AND ANTI-LAG-3 ACTIVE AGENT FOR TREATING CANCER | ALSOMAIRY, SARAH ABDOALATIF | 28d overdue |
| 18179838 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | TOWNSLEY, SARA ELIZABETH | 28d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18824281 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | CHEN, PO-CHIH | 295d overdue |
| 18330141 | COMBINATION THERAPY OF ANTI-PD-1 ACTIVE AGENT, ANTI-TIM-3 ACTIVE AGENT, AND ANTI-LAG-3 ACTIVE AGENT FOR TREATING CANCER | ALSOMAIRY, SARAH ABDOALATIF | 28d overdue |
| 18179838 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | TOWNSLEY, SARA ELIZABETH | 28d overdue |
| 18176294 | TOPICAL TREATMENT OF VITILIGO BY A JAK INHIBITOR | GOTFREDSON, GAREN | 3d overdue |
| 18625703 | NOVEL PD-1 BINDING DOMAINS | GAO, ASHLEY HARTMAN | 15d |
| 18162955 | COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF | NATARAJAN, MEERA | 26d |
| 18373648 | ANTI-PD-1/LAG-3 BISPECIFIC ANTIBODIES AND USES THEREOF | REDDIG, PETER J | 27d |
| Art Unit | Apps |
|---|---|
| 1646 | 3 |
| 1629 | 2 |
| 1621 | 1 |
| 1678 | 1 |
| 1622 | 1 |
| 1619 | 1 |
| 1643 | 1 |
| 1699 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18824281 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | CHEN, PO-CHIH | 1621 | §103 | Non-Final OA | 295d overdue | Pending | Sep 04, 2024 |
| 18625703 | NOVEL PD-1 BINDING DOMAINS | GAO, ASHLEY HARTMAN | 1678 | Other | Final Rejection | 15d | Pending | Apr 03, 2024 |
| 18373648 | ANTI-PD-1/LAG-3 BISPECIFIC ANTIBODIES AND USES THEREOF | REDDIG, PETER J | 1646 | Other | Non-Final OA | 27d | Pending | Sep 27, 2023 |
| 18232970 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | REDWOOD, CHRISTOPHER EVAN | 1629 | §103 | Non-Final OA | 25d overdue | Pending | Aug 11, 2023 |
| 18349606 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS | DEKARSKE, MADELINE MCGUIRE | 1622 | Other | Non-Final OA | 46d | Pending | Jul 10, 2023 |
| 18330141 | COMBINATION THERAPY OF ANTI-PD-1 ACTIVE AGENT, ANTI-TIM-3 ACTIVE AGENT, AND ANTI-LAG-3 ACTIVE AGENT FOR TREATING CANCER | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §101 | Non-Final OA | 28d overdue | AI Ready | Jun 06, 2023 |
| 18179838 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | TOWNSLEY, SARA ELIZABETH | 1629 | §103 | Non-Final OA | 28d overdue | Pending | Mar 07, 2023 |
| 18176294 | TOPICAL TREATMENT OF VITILIGO BY A JAK INHIBITOR | GOTFREDSON, GAREN | 1619 | Other | Non-Final OA | 3d overdue | AI Ready | Feb 28, 2023 |
| 18162955 | COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF | NATARAJAN, MEERA | 1643 | §103 | Final Rejection | 26d | Pending | Feb 01, 2023 |
| 18092610 | PD-L1/STING CONJUGATES AND METHODS OF USE | JARRELL, NOBLE E | 1699 | Other | Non-Final OA | 51d overdue | Pending | Jan 03, 2023 |
| 17991482 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | VALLE, ERNESTO | 1623 | §103 | Final Rejection | 7d | Pending | Nov 21, 2022 |
| 18056907 | MULTISPECIFIC BINDING MOIETIES COMPRISING PD-1 AND TGF-BRII BINDING DOMAINS | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102 | Non-Final OA | 15d | Pending | Nov 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial